Ian J. Okazaki

3.7k total citations · 1 hit paper
25 papers, 2.0k citations indexed

About

Ian J. Okazaki is a scholar working on Immunology, Oncology and Physiology. According to data from OpenAlex, Ian J. Okazaki has authored 25 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 18 papers in Oncology and 15 papers in Physiology. Recurrent topics in Ian J. Okazaki's work include PARP inhibition in cancer therapy (16 papers), Toxin Mechanisms and Immunotoxins (16 papers) and Calcium signaling and nucleotide metabolism (14 papers). Ian J. Okazaki is often cited by papers focused on PARP inhibition in cancer therapy (16 papers), Toxin Mechanisms and Immunotoxins (16 papers) and Calcium signaling and nucleotide metabolism (14 papers). Ian J. Okazaki collaborates with scholars based in United States and United Kingdom. Ian J. Okazaki's co-authors include Joel Moss, Jeffrey S. Miller, Gong Yun, Paul J. Orchard, Arne Slungaard, Susan K. Fautsch, David H. McKenna, Bruce R. Blazar, Chap T. Le and Angela Panoskaltsis‐Mortari and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Ian J. Okazaki

24 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer

2005 1.4k citations Jeffrey S. Miller, Yvette Soignier et al. Blood profile →

Peers

Countries citing papers authored by Ian J. Okazaki

Since Specialization

Citations

This map shows the geographic impact of Ian J. Okazaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian J. Okazaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian J. Okazaki more than expected).

Fields of papers citing papers by Ian J. Okazaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian J. Okazaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian J. Okazaki. The network helps show where Ian J. Okazaki may publish in the future.

Co-authorship network of co-authors of Ian J. Okazaki

This figure shows the co-authorship network connecting the top 25 collaborators of Ian J. Okazaki. A scholar is included among the top collaborators of Ian J. Okazaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian J. Okazaki. Ian J. Okazaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integrated CTC- and EV-based detection of PSMA protein and efficacy of ¹⁷⁷ Lu-PSMA-617 radioligand therapy. 2025 ·Journal of Clinical Oncology ·(unknown), Megan Ludwig, Anne Eaton, (unknown), (unknown), (unknown), (unknown), Gautam Jha, Ian J. Okazaki, Charles J. Ryan, Nicholas A. Zorko, Yingchun Zhao, Zuzan Caycı, Scott M. Dehm, Jiarong Hong, Peter W. Villalta, (unknown), Justin M. Drake, Emmanuel S. Antonarakis	0
2	Thrombophilia testing has limited usefulness in clinical decision-making and should be used selectively 2015 ·Journal of Vascular Surgery Venous and Lymphatic Disorders ·Elna M. Masuda, (unknown), Ian J. Okazaki, (unknown), Robert L. Kistner	6
3	Autologous Large Multivalent Immunogen Vaccine in Patients With Metastatic Melanoma and Renal Cell Carcinoma 2008 ·American Journal of Clinical Oncology ·Arkadiusz Z. Dudek, Matthew F. Mescher, Ian J. Okazaki, (unknown), Xianghua Luo, Julie Curtsinger, Jeffrey S. Miller	19
4	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer breakdown → 2005 ·Blood ·Jeffrey S. Miller, Yvette Soignier, Angela Panoskaltsis‐Mortari, (unknown), Gong Yun, Susan K. Fautsch, David H. McKenna, Chap T. Le, Todd E. DeFor, Linda J. Burns, Paul J. Orchard, Bruce R. Blazar, John E. Wagner, Arne Slungaard, Daniel J. Weisdorf, Ian J. Okazaki, Philip B. McGlave	1428
5	Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells. 2004 ·Blood ·Jeffrey S. Miller, Yvette Soignier, (unknown), David H. McKenna, Chap T. Le, Todd E. DeFor, Linda J. Burns, Paul J. Orchard, Bruce R. Blazar, John E. Wagner, Arne Slungaard, Daniel J. Weisdorf, Ian J. Okazaki, Philip B. McGlave	2
6	Identification of Regulatory Domains in ADP-ribosyltransferase-1 That Determine Transferase and NAD Glycohydrolase Activities 2003 ·Journal of Biological Chemistry ·Christelle Bourgeois, Ian J. Okazaki, (unknown), Maria S. Nightingale, Joel Moss	10
7	Purine Metabolites Suppress Proliferation of Human NK Cells Through a Lineage-Specific Purine Receptor 1999 ·The Journal of Immunology ·Jeffrey S. Miller, (unknown), (unknown), Ian J. Okazaki, Joel Moss	39
8	Glycosylphosphatidylinositol-anchored and Secretory Isoforms of Mono-ADP-ribosyltransferases 1998 ·Journal of Biological Chemistry ·Ian J. Okazaki, Joel Moss	66
9	Characterization of Mouse Rt6.1 NAD:Arginine ADP-ribosyltransferase 1997 ·Journal of Biological Chemistry ·Joel Moss, Linda A. Stevens, (unknown), Ian J. Okazaki, Rita Bortell, (unknown), John P. Mordes, Dale L. Greiner, Aldo A. Rossini	18
10	An 18-kDa Domain of a Glycosylphosphatidylinositol-linked NAD:Arginine ADP-Ribosyltransferase Possesses NAD Glycohydrolase Activity 1997 ·Journal of Biological Chemistry ·Hyunju Kim, Ian J. Okazaki, Tatsuyuki Takada, Joel Moss	6
11	ADP-Ribosylarginine Hydrolases and ADP-Ribosyltransferases 1997 ·Advances in experimental medicine and biology ·Joel Moss, Anna Żółkiewska, Ian J. Okazaki	29
12	Molecular Cloning and Characterization of Lymphocyte and Muscle ADP-Ribosyltransferases 1997 ·Advances in experimental medicine and biology ·Ian J. Okazaki, Hyunju Kim, Joel Moss	2
13	Mono-ADP-ribosylation: A Reversible Posttranslational Modification of Proteins 1996 ·Advances in pharmacology ·Ian J. Okazaki, Joel Moss	44
14	Cloning and Characterization of a Novel Membrane-associated Lymphocyte NAD:Arginine ADP-ribosyltransferase 1996 ·Journal of Biological Chemistry ·Ian J. Okazaki, Hyunju Kim, Joel Moss	54
15	Structure and function of eukaryotic mono-ADP-ribosyltransferases 1996 ·PubMed ·Ian J. Okazaki, Joel Moss	19
16	Vertebrate mono-ADP-ribosyltransferases 1994 ·Molecular and Cellular Biochemistry ·Anna Żółkiewska, Ian J. Okazaki, Joel Moss	22
17	ADP-ribosylarginine hydrolases 1994 ·Molecular and Cellular Biochemistry ·Tatsuyuki Takada, Ian J. Okazaki, Joel Moss	14
18	Common structure of the catalytic sites of mammalian and bacterial toxin ADP-ribosyltransferases 1994 ·Molecular and Cellular Biochemistry ·Ian J. Okazaki, Joel Moss	19
19	Immunological and structural conservation of mammalian skeletal muscle glycosylphosphatidylinositol-linked ADP-ribosyltransferases 1994 ·Biochemistry ·Ian J. Okazaki, Anna Żółkiewska, Maria S. Nightingale, Joel Moss	68
20	Inhibition of arachidonic acid incorporation into erythrocyte phospholipids by peracetic acid and other peroxides. Role of arachidonoyl-CoA: 1-palmitoyl-sn-glycero-3-phosphocholine acyl transferase 1991 ·Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism ·David W. Allen, Lisa M. Newman, Ian J. Okazaki	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact